Speaker illustration

Professor Shenghua Zhou

The Second Xiangya Hospital of Central South University, Changsha (China)

Low-dose rivaroxaban during the acute phase of ACS - H-REPLACE Trial)

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Late Breaking Trials in ACS

Thumbnail

This platform is supported by

logo Novo Nordisk